The 2nd edition of FT US Pharma and Biotech Summit will provide a fresh perspective on the crucial issues impacting the pharma and biotech industries today. Senior industry leaders will share their insights, ideas and expertise on topics such as the pharma pricing and politics, the future of gene editing, tracking China’s pharma growth market and the opportunities and challenges of unconventional partnerships and collaborations across the new healthcare landscape.
FT US Pharma and Biotech Summit 2020
With The Support Of
Global Clinical Research Partner
Agenda - 14th May
9:00amOpening Remarks from the Chair
9:05amKeynote Address/ Interview
9:20amPanel: Pharma Pricing and Politics: From Rhetoric to Action?
The issue of rising drug prices remains front and centre of the political debate in the 2020 election year. A host of proposals have been put forward in recent months by the Senate Finance Committee, House Democrats and the White House to hold the pharma industry ‘accountable for its actions’. While current proposals are mired in political uncertainly, the proposals of the 2020 Presidential candidates provide a clear indication that the issue of drug pricing is likely to be central to the legislative agenda post election. If some of the more hard-hitting measures come to light, the implications for the underlying economic model of the industry are potentially profound.
- What healthcare reforms are being proposed by 2020 presidential candidates and how could they affect drug prices?
- What is the good, the bad and the ugly of the multitude of proposed reforms on the table? What are the proposals which could make a meaningful impact on drug prices?
- Will biosimilars make a real impact on drug prices, or it is time to throw in the towel? What are the measures that could drive uptake an acceptance by physicians and patients?
- Should patent reforms and attempts to address ‘evergreening’ and ‘patent thickets’ play a bigger role of the debate?
- Are subscription models the way ahead for paying for one-time cures?
10:10amThe FT Big Debate: Is Government - Driven R&D the Way Forward?
Is it time for a fundamental rethink of the way fund R&D? Amid the furore over ever rising drug prices, shortages of essential medicines and a lack of return on government-backed investment in patented drugs, a rising tide of voices are speaking in favour of a ‘public option’ - the creation and expansion of public institutions across the entire pharma value chain from R&D, to manufacturing, to wholesale and distribution in order to create ’a safe and accessibly priced supply of essential medicines’. A ‘public option', it is claimed, would spur private sector innovation and lower prices. In the same vein, the possibility of alternative models to include a 'cost plus returns' models to pay for pharma industry drugs is also raised for consideration. And the phenomenon is not exclusive to the US. In the UK, the opposition Labour Party has raised the shackles of the industry with talk of a state run drugs company to supply the UK’s national healthcare system. Do we need a public option for pharma R&D? How might such a system work? Where does innovation happen best – what is the proof that publicly funded or procured research would yield better and less expensive drugs?
10:50amNetworking Coffee Break
11:10amThe Payer’s Perspective on Value
11:25amBig Tech, Big Pharma: Bridging a Pharma-Digital Divide? Unconventional Partnerships and Collaborations in Pharma
As pharma companies navigate the new world of digital and value, they are working in close partnerships with players from the world of big tech and big data. Among the many benefits, these relationships allow pharma companies to leverage expertise, talent, build closer relationships with patients and gain a foothold, for instance, in the fast-growing business of digiceuticals and AI-driven products and services. Yet it is often remarked that an unspoken divide separates the ‘parallel worlds’ of pharma and tech, preventing closer alignment and realizing the full potential that such partnerships can offer. The ‘glacial pace of decision-making’ and siloed world of in pharma is often contrasted with the more ‘agile and open’ world of tech.
- How real is the ‘cultural divide between pharma and data companies? What have been the experiences of such partnership to date? How synergistic are the relationships?
- How are pharma companies and their digital partners navigating challenges of IP, data rights, sharing and ownership and attributing value in such joint endeavours? How are partnership models evolving?
- How vital are partnerships: could pharma ‘go it alone’ on AI and digital therapeutics?
12:15pmKeynote Address/ Interview
1:30pmThinking Big: Tracking China’s Pharma Growth
China is stepping up its investment in life sciences and is aiming to take a lead in drug development, AI, gene editing and gene therapies. It is also now the second largest pharmaceutical in the world and is set to be the first within 7-10 years. Recent moves by the industry regulator are paving the way for faster drug approvals and greater access for patients to advanced therapies. China is embracing digital at a pace which eclipses the efforts in most other countries, and lacking the burden of legacy primary health care systems, is creating innovate new treatment and service models. Having a strategic presence in China is now considered paramount.
In the immediate term, however, a looming trade war and the impacts of restrictive foreign investment rules in the form of CIFUS are expected to play a moderating role on the potential for closer US-China life science collaboration.
- How is healthcare reform and the regulatory environment for life sciences in China evolving and what does it mean for pharma?
- How is digital health evolving in China? What innovative approaches and strategies is China adopting to deal with ageing and management of chronic diseases? What are the implications of China’s approach to data as a public asset?
- Will China be a leader or follower in drug development? What is the true level of innovation and ambition in China - the vision of China innovation 2020/2025?
- If a rising tide China’s innovator drugs can undercut US prices, should the US industry be on notice?
- What will be the impact of China-US trade wars and CIFUS?
2:20pmDawn of a Brave New World? The Future of Gene Editing
Rapid progress experienced in the field of gene editing in recent year holds the promise of finding cures for some of the most severe diseases including recessive genetic disorders as well as acquired disorders associated with genetic mechanisms including cancer. Yet there remain safety, ethical and, governance hurdles including societal acceptance and uncertainty regarding longer term effects to overcome before the benefits of the technology can reach patients in the clinic.
- What are the potential therapeutic options?
- How is the science evolving to limit off-target effects? How could advances in the pioneering field of functional genomics alter the paradigm of gene editing?
- In formulating global governance and ethical frameworks for gene editing, where should we draw the line between risk and opportunity - between concerns of safety on the one hand, and halting scientific progress on the other?
3:45pmPanel: New Approaches for a New Age of Mental Health
Over 46 million Americans suffer from mental illness, yet difficulties experienced in gaining access to treatment specialists and a dearth of new psychiatric drugs has left patients with ever more limited treatment options. The cost and complexity of research in the field of mental illness has seen the withdrawal of big pharma from the field of psychiatric drug research over the past decades. Yet new research in the field of genomics and mental health and in emerging areas to include immunemodality drugs, psychedelics and beyond, as well as new efforts to better understand the biology of the brain and mental illness hold the promise of new drugs in the future.
Meanwhile, a new wave of apps and other digital interventions are is rapidly changing the way mental health care is delivered, extending delivery beyond pills and traditional, in-person sessions to offer around-the-clock support from remote physicians or tech-driven tools that reach the patient wherever they are. Healthcare providers and pharma companies alike are looking increasingly to provide digital mental health offerings, often in partnership with start-ups.
- What might be the next leap forward in psychiatric pharmacology?
- What is the potential for genomics in mental health?
- What are the advances in our understanding of biology of the brain and mental health which hold the promise for new drugs?
- What is the potential and the challenges (e.g dealing with high-risk scenarios) with the new generation of digital apps and treatments?
4:30pmInnovation Showcase/ Breakthrough Science: Beyond Opioids - Next Frontiers in Pain Medicine and Management
A contributing factor to the opioid crisis which has paralysed America and is now being felt in a growing number of countries is the absence of effective alternatives to pain modification and management.
Despite current therapeutics and interventions, pain continues to pose a significant burden to patients and the healthcare system on a global scale. The number of adults living with chronic pain in the United States annually exceeds those living with cancer, diabetes and heart disease combined, and approximately one quarter of these people endure severe pain on a daily basis.
This concluding session of the Summit will highlight some of the emerging innovation in alternative, non-opioid pain medicines and therapies and review their markets potential.
5:00pmClosing Remarks from the FT Chair
Sarah Neville is Global Pharmaceuticals Editor of the Financial Times, a position she has held since 2016. She joined the Financial Times in 2001 and has held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and Public Policy Editor. She began her career on local and regional newspapers, eventually becoming Political Editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post.
Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York. Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.
Companies in attendance in 2019
Sanofi • FDA • Eisai • Bayer • AstraZeneca • Novartis Pharmaceuticals • Mylan • Otsuka • GlaxoSmithKline • Eli Lilly • Pfizer • National Pharmaceutical Council • Takeda • UCB • Janssen • Vitruvian Biomedical • Bristol Myers Squibb • BioMarin Pharmaceutical Inc • Aquestive Therapeutics • Johnson & Johnson • Ibex Biosciences • Bound Therapeutics LLC • Horizon Pharma • Spark Therapeutics • Celgene • Regeneron Pharmaceuticals • CONTINUUS Pharmaceuticals and many others.
- Gain insights into the healthcare reforms being proposed by US Presidential candidates and how they might affect pharma pricing and risk
- Hear how payer’ perspectives on value is evolving
- Discuss the challenges and opportunities of unconventional partnerships in pharma and the myth and reality of pharma’s digital divide
- Debate whether governments should play a bigger role in drug development as ROI diminishes, shortages increase and price of drugs continue to rise
- Get the inside story on whether China will be a leader or follower in life sciences as the county’s level of ambition and innovation increases
- Discover the latest development in gene editing and have your say on where we should draw the line between risk and opportunity
The FT US Pharma & Biotech Summit will be attended by CEOs, CFOs, CTOs CIOs, Head of R&D, Chief Medical Officers, Chief Strategy Officers, Chief Digital Officers, Market Access and Pricing, Chief Business Officers and other senior-level executives in the following sectors:
- Pharmaceutical & Biotechnology Companies
- Pharmaceutical Wholesalers/PBMs
- Healthcare insurers and government payers
- Government healthcare departments and agencies
- IT, big data and analytics providers
- Medical Device Manufacturers
- Investment bankers, private equity and VCs
- Patient representatives and health-related NGOs
- Gain access to 250 executives and leaders from across the US pharmaceutical industry;
- Brand alignment with the FT and its unrivalled credibility;
- Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
- Benefit from sustained international visibility through our advertising and marketing campaigns
Head of Portfolio
PRESENTED BY (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.
With the support of (1)
About Life Sciences and Health Care at Deloitte
Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
Global Clinical Research Partner (1)
ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.
ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.
With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 40 countries and has approximately 14,500 employees. For further information please visit www.iconplc.com Follow @iconplc on Twitter.